1. Home
  2. PGZ vs LUNG Comparison

PGZ vs LUNG Comparison

Compare PGZ & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Principal Real Estate Income Fund of Beneficial Interest

PGZ

Principal Real Estate Income Fund of Beneficial Interest

HOLD

Current Price

$10.17

Market Cap

67.9M

Sector

Finance

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.90

Market Cap

57.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PGZ
LUNG
Founded
2012
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Industrial Specialties
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
67.9M
57.9M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
PGZ
LUNG
Price
$10.17
$1.90
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$5.38
AVG Volume (30 Days)
17.4K
629.0K
Earning Date
01-01-0001
04-29-2026
Dividend Yield
12.26%
N/A
EPS Growth
N/A
7.64
EPS
N/A
N/A
Revenue
N/A
$90,497,000.00
Revenue This Year
N/A
$2.48
Revenue Next Year
N/A
$18.46
P/E Ratio
N/A
N/A
Revenue Growth
N/A
8.01
52 Week Low
$9.32
$1.13
52 Week High
$10.64
$2.89

Technical Indicators

Market Signals
Indicator
PGZ
LUNG
Relative Strength Index (RSI) 51.60 65.12
Support Level $10.01 $1.27
Resistance Level $10.32 $2.14
Average True Range (ATR) 0.11 0.17
MACD -0.02 0.08
Stochastic Oscillator 38.24 74.36

Price Performance

Historical Comparison
PGZ
LUNG

About PGZ Principal Real Estate Income Fund of Beneficial Interest

Principal Real Estate Income Fund is a non-diversified, closed-end management investment company. Its investment objective is to provide high current income with capital appreciation by investing in commercial real estate-related securities. The company does its investments in USA, Australia, Japan, France, Great Britain, Canada, Hong Kong, Singapore, South Korea, British Virgin Islands and more.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: